Metoprolol tartrate is an immediate-release formulation. It is absorbed quickly, reaches peak blood levels within one to two hours, and is typically dosed two or three times per day. The extended-release version of metoprolol uses a different salt form, metoprolol succinate, which is designed to release the drug slowly over a full 24-hour period and is taken once daily. The two are not interchangeable milligram-for-milligram, and the distinction matters more than many patients realize.
Why Two Salt Forms Exist
Metoprolol is a beta-blocker that slows the heart rate and lowers blood pressure by blocking the effects of adrenaline on beta-1 receptors in the heart. The active molecule is the same in both products, but it is paired with different chemical partners. In metoprolol tartrate, the drug is bound to tartaric acid, producing a salt that dissolves rapidly in the stomach and enters the bloodstream fast. In metoprolol succinate, the drug is bound to succinic acid and packaged inside a delivery system engineered to release metoprolol gradually.
The practical upshot is straightforward: metoprolol tartrate gives you a quick spike in drug levels that fades relatively fast, so you need multiple doses throughout the day to maintain coverage. Metoprolol succinate, sold under the brand name Toprol-XL, delivers a steadier stream of the drug so that one pill in the morning keeps working until the next morning. The MERIT-HF trial, one of the largest studies of beta-blockers in heart failure, noted that the controlled-release succinate formulation produces “a more pronounced and even β-blockade over 24 hours” compared with immediate-release tartrate tablets given three times per day.1JAMA. Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart Failure
How the Extended-Release Tablet Actually Works
Metoprolol succinate extended-release tablets are not simply a slow-dissolving chunk of drug. Each tablet contains a large number of tiny controlled-release pellets, and each pellet acts as its own independent drug delivery unit designed to release metoprolol continuously over the dosing interval.2PubMed. Tablet splitting: Product quality assessment of metoprolol succinate extended release tablets This multi-pellet design is important because it means the tablet does not rely on a single matrix layer to control the release rate. Even if a tablet is scored and split in half, many of those pellets should theoretically still function. In practice, though, splitting these tablets introduces real variability. Research has found that the uneven distribution of pellets across the tablet surface leads to large differences in weight and drug content between the two halves after splitting.2PubMed. Tablet splitting: Product quality assessment of metoprolol succinate extended release tablets If your doctor prescribes a dose that requires splitting an extended-release tablet, this inconsistency is worth knowing about.
The design goal for a 24-hour extended-release metoprolol product is a specific dissolution curve: no more than about 25% of the drug released in the first hour, a gradual ramp through the middle hours, and at least 80% released by the 20th hour.3International Journal of Pharmaceutical Sciences and Nanotechnology. Formulation and In vitro Release Characterization of Metoprolol Succinate Extended Release Tablets Metoprolol tartrate, by contrast, dumps its full dose into the bloodstream almost immediately.
Dosing Differences and Why They Are Not Interchangeable
Because the two formulations deliver metoprolol to the body so differently, switching between them is not as simple as taking the same number of milligrams. A common immediate-release regimen for metoprolol tartrate is 50 mg taken two or three times daily, totaling 100 to 150 mg per day. The equivalent extended-release succinate dose might be a single 100 mg or 200 mg tablet once daily, but the peak blood levels are much lower with the extended-release version because the drug trickles in rather than flooding the system all at once. The MERIT-HF investigators pointed out that the target dose could be pushed up to 200 mg once daily with the extended-release formulation without increasing peak plasma concentration, something that would not be possible with a single large dose of the immediate-release form.1JAMA. Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart Failure
This means that if a pharmacy substitutes one form for the other without adjusting the dose and frequency, the patient could end up with too little drug coverage (if switched from tartrate three times daily to a once-daily succinate dose that is too low) or too much drug hitting the system at once (if switched from succinate to a single large tartrate dose). If you ever see a change in the name or appearance of your metoprolol prescription, check whether the salt form changed.
When Each Formulation Is Preferred
Both forms are prescribed widely, but they tend to fill different clinical roles. Metoprolol tartrate is commonly used in acute or short-term settings. Its rapid onset makes it useful when a doctor wants to bring heart rate or blood pressure down quickly, such as around the time of a heart attack or during certain hospital stays. A review in a cardiovascular medicine journal described metoprolol tartrate as the go-to immediate-release option in acute myocardial infarction settings, while the succinate form is preferred for chronic management.4European Journal of Cardiovascular Medicine. Role of ß-Blocker Metoprolol in Acute Myocardial Infarction
Metoprolol succinate extended-release has the stronger evidence base in chronic heart failure. In the MERIT-HF trial, extended-release metoprolol succinate reduced the risk of death from any cause by about a third compared with placebo, cut sudden cardiac death by roughly 40%, and reduced the combined rate of death and hospitalization by about a fifth.5PubMed. Extended-release metoprolol succinate in chronic heart failure These results were specifically demonstrated with the extended-release succinate formulation, and current heart failure guidelines reflect that. Patients sometimes assume that because the active molecule is the same, the tartrate version can substitute freely for heart failure treatment. The evidence does not support that assumption, at least not at the same dose and schedule that was studied in the landmark trials.
For straightforward high blood pressure in a patient who does not have heart failure, either form can work. The choice often comes down to convenience and cost. Once-daily dosing with the succinate is easier to remember, but generic metoprolol tartrate tends to be cheaper, and some patients manage fine with twice-daily dosing.
Can Metoprolol Tartrate Be Made Into an Extended-Release Product?
This is a question that has actually been explored in pharmaceutical research. The tartrate salt dissolves so readily that creating a slow-release version of it requires special formulation work. Researchers have developed extended-release matrix tablets using metoprolol tartrate by embedding it in polymers that swell in the gut and release the drug gradually. One study created 100 mg metoprolol tartrate extended-release tablets using different grades and levels of a cellulose-based polymer, testing direct compression, fluid-bed granulation, and high-shear granulation methods to find a formulation sensitive enough to serve as a model for regulatory evaluation of modified-release dosage forms.6PubMed. Development of metoprolol tartrate extended-release matrix tablet formulations for regulatory policy consideration
So it is technically possible to slow down the release of metoprolol tartrate, but the commercially available extended-release products on the market use the succinate salt. If your prescription says “metoprolol tartrate,” you are getting an immediate-release product unless a pharmacist or prescriber has specifically arranged otherwise through a compounding pharmacy, which is uncommon.
Food and the Extended-Release Formulation
Patients often wonder whether to take their metoprolol with food. For the immediate-release tartrate, food can actually increase how much drug reaches the bloodstream, which is why some prescribing information suggests taking it with meals. The extended-release formulation appears less sensitive to this variable. Research on a controlled-release metoprolol delivery system found that food intake did not significantly affect the plasma concentration profiles, peak levels, or total drug absorbed. Roughly 80 to 90% of the absorbed drug reached the bloodstream within 10 hours regardless of whether the patient had eaten.7PubMed Central. Influence of food on the absorption of metoprolol administered as an Oros drug delivery system to man The consistency of drug delivery is part of the appeal of the extended-release version: fewer variables to worry about in your daily routine.
Why Your Genetics Might Change How Either Form Affects You
Whether you take the tartrate or the succinate, your body breaks down metoprolol primarily through a liver enzyme called CYP2D6. Genetic variation in CYP2D6 is remarkably common, and it can dramatically alter how much metoprolol actually circulates in your blood after you swallow a pill. A pooled analysis of multiple studies found that people who are “poor metabolizers” of CYP2D6 end up with peak metoprolol blood levels about 2.3 times higher and overall drug exposure nearly five times higher than normal metabolizers. At the other extreme, ultrarapid metabolizers clear the drug so fast that their exposure is roughly 13 times lower than that of poor metabolizers.8PubMed Central. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics
Those are not small differences. A poor metabolizer on a standard dose of metoprolol is effectively getting several times the intended drug exposure, which can translate to real clinical problems. A retrospective study of over 300 patients with CYP2D6 genotyping results found that poor metabolizers had significantly higher rates of bradycardia (abnormally slow heart rate) compared with normal metabolizers, and their average heart rates were measurably lower.9PubMed Central. Metoprolol and CYP2D6: A Retrospective Cohort Study Evaluating Genotype-Based Outcomes Dutch pharmacogenomics guidelines already recommend slower dose increases and lower target doses for poor metabolizers, as well as for normal metabolizers who take other medications that strongly inhibit CYP2D6.9PubMed Central. Metoprolol and CYP2D6: A Retrospective Cohort Study Evaluating Genotype-Based Outcomes
This genetic factor applies to both formulations, but it can interact with the release profile in different ways. With immediate-release tartrate, a poor metabolizer experiences a particularly high spike in drug levels after each dose. With extended-release succinate, the peak is blunted, but the sustained elevation in drug levels lasts around the clock. Neither scenario is inherently safer for a poor metabolizer; both require dose adjustment. If you have ever felt unusually fatigued, dizzy, or had a very low heart rate on metoprolol at what seemed like a normal dose, genetic variation in CYP2D6 is one possible explanation worth discussing with your doctor.
Drug Interactions That Mimic Genetic Effects
You do not need to carry a CYP2D6 variant to experience poor-metabolizer-like effects. Certain common medications strongly inhibit CYP2D6 and can convert a normal metabolizer into what pharmacologists call a “phenoconverter,” someone whose enzyme behaves as if it were genetically impaired. The retrospective study mentioned above included phenoconverters as a distinct group and found that their average heart rates were about 2.6 beats per minute lower than those of normal metabolizers.9PubMed Central. Metoprolol and CYP2D6: A Retrospective Cohort Study Evaluating Genotype-Based Outcomes Some of the medications that can cause this include certain antidepressants (fluoxetine and paroxetine are well-known strong CYP2D6 inhibitors), the antiarrhythmic drug quinidine, and the antifungal terbinafine. If you start or stop one of these medications while taking metoprolol, it can meaningfully change how much metoprolol your body is exposed to, regardless of which salt form you use.
Crushing, Splitting, and Nasogastric Tubes
An immediate-release metoprolol tartrate tablet can generally be crushed or split without affecting how the drug works, because there is no controlled-release mechanism to damage. This makes tartrate the preferred form for patients who cannot swallow whole tablets or who receive medications through a feeding tube.
Extended-release metoprolol succinate tablets present a more complicated picture. As noted earlier, each tablet contains many tiny controlled-release pellets. Crushing the tablet would destroy those pellets and convert the entire dose into what is essentially an immediate release, which could cause a dangerous spike in blood levels. Even splitting, which preserves most of the pellets, introduces enough variability in how much drug ends up in each half that the consistency advantage of extended-release dosing is partly undermined. For patients who need tube feeding or have difficulty swallowing, metoprolol tartrate given in smaller, more frequent doses is generally the safer choice.
Recognizing Which Form You Have
Pharmacy labels do not always make the distinction obvious, especially with generics. Here are the reliable identifiers:
- Salt name: “Metoprolol tartrate” is always immediate-release. “Metoprolol succinate” is always extended-release in commercially available products.
- Dosing frequency: If the label says to take it two or three times daily, it is almost certainly tartrate. Once daily points to succinate extended-release.
- Brand names: Lopressor is the well-known brand for the tartrate. Toprol-XL is the brand for the succinate extended-release. Generics should specify the salt on the label.
- Tablet markings: When in doubt, look up the imprint code on the tablet using your pharmacist or an online pill identifier. The two forms come in different shapes and strengths.
Confusion between the two forms is common enough that it has been flagged as a medication safety concern. If you are picking up a refill and the pills look different from what you have been taking, ask the pharmacist to confirm which salt form you are receiving before assuming it is a routine generic swap.
Cost and Access Considerations
Generic metoprolol tartrate is one of the cheapest cardiovascular drugs available, often costing just a few dollars a month. Generic metoprolol succinate extended-release is also affordable compared with many brand-name heart medications, but it typically costs more than the tartrate. For patients without insurance or with high copays, the price difference can matter. Some patients and prescribers make a deliberate choice to use tartrate two or three times a day to save money, accepting the inconvenience of multiple daily doses. This is a reasonable strategy for hypertension in otherwise healthy people, but for heart failure, the clinical evidence specifically supports the extended-release succinate, and switching to tartrate solely for cost reasons should involve a careful conversation with a cardiologist about whether the tradeoff is appropriate.